findmyKOL
Clinical trialNCT00027339CompletedPhase 2Interventional

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment53HIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Because people infected with HIV strains that are resistant to anti-HIV drugs have fewer effective treatment options, selecting an effective anti-HIV drug combination is difficult. A combination of protease inhibitors (PIs), when added to a patient's current anti-HIV therapy, may decrease viral load and increase drug activity. Tests that measure drug levels in the blood and tests to evaluate the drug resistance of HIV may also be helpful in choosing the best anti-HIV drug combination for a patient. This study will determine whether using these tests to choose a drug combination and adding PIs to that combination will improve the patient's response to anti-HIV therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico
  • Puerto Rico-Aids Crs

    San Juan, Puerto Rico

United States
  • Usc Crs

    Los Angeles, California, United States

  • Stanford Crs

    Palo Alto, California, United States

  • Uc Davis Medical Center

    Sacramento, California, United States

  • Ucsd, Avrc Crs

    San Diego, California, United States

  • University of Colorado Hospital Crs

    Aurora, Colorado, United States

  • Univ. of Miami Aids Crs

    Miami, Florida, United States

  • Indiana Univ. School of Medicine, Wishard Memorial

    Indianapolis, Indiana, United States

  • Methodist Hosp. of Indiana

    Indianapolis, Indiana, United States

  • Beth Israel Med. Ctr., Actu

    New York, New York, United States

  • Ny Univ. Hiv/aids Crs

    New York, New York, United States

  • Unc Aids Crs

    Chapel Hill, North Carolina, United States

  • Duke Univ. Med. Ctr. Adult Crs

    Durham, North Carolina, United States

  • Vanderbilt Therapeutics Crs

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fosamprenavir →Indinavir →Lopinavir →Ritonavir →Tenofovir disoproxil →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
30 Jun 2005
Last update posted
1 Nov 2021
Registered enrollment
53
Registry id
NCT00027339
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.